PET imaging of dopamine transporters with [18F]FE-PE2I: Effects of anti-parkinsonian drugs : 항파킨슨병 약물이 도파민 운반체 PET 방사성 추적자 [18F]FE-PE2I의 도파민 운반체 결합에 미치는 영향

Cited 0 time in Web of Science Cited 0 time in Scopus


의과대학 의학과
Issue Date
서울대학교 대학원
Parkinson diseaseDopamine transporter(E)-N-(3-iodoprop-2-enyl)-2beta-carbofluoroethoxy-3beta-(4'-methyl-phenyl) nortropaneLevodopaPositron-Emission Tomography
학위논문 (석사)-- 서울대학교 대학원 : 의학과(뇌신경과학 전공), 2015. 8. 김상은.
[18F]FE-PE2I is a promising radioligand for dopamine transporter (DAT) imaging. This study aimed to determine any correlation between striatal [18F]FE-PE2I binding and immunohistochemical (IHC) stain of tyrosine hydroxylase (TH) in the striatum, and to evaluate the effects of therapeutic drugs on [18F]FE-PE2I binding.
Materials and Methods:
Dynamic PET/CT of [18F]FE-PE2I was performed on Parkinsons disease (PD) rat models, induced by unilateral injection of 6-OHDA into the striatum. A simplified reference tissue model using the cerebellum as a reference was used to calculate the striatal binding potential (striatal BPND). Ratio of optical density (OD) of TH-reactive fibers in the PD and normal rats was correlated with ratio of striatal BPND. To study therapeutic drug effects, each of the 4 normal rats were pretreated with L-DOPA combined with benserazide, pramipexole, amantadine and escitalopram 30 min before [18F]FE-PE2I injection. The L-DOPA/benserazide effect on lesioned and unlesioned striatal BPND was also assessed in the PD rats.

The BPND was significantly lower in the lesioned striatum than in the unlesioned one or the striatum of normal rats. The ratio of OD of TH-reactive fibers linearly correlated with the ratio of striatal BPND (r=0.741, P<0.05). After the pre-treatment with pramipexole, amantadine and escitalopram, the values of striatal BPND did not differ from those of control rats. However, pre-treatment of L-DOPA/benserazide significantly reduced the striatal BPND (P=0.03). The striatal BPND of PD rats with L-DOPA/benserazide was not different from those of same PD rats with placebo (normal saline) treatment. For midbrain binding, pretreatment of escitalopram did not affect the midbrain BPND on normal rats.

[18F]FE-PE2I may be used as a radioligand for in vivo imaging of the DAT. In normal rats, [18F]FE-PE2I binding is unaffected by therapeutic drugs for PD including pramipexole, amantadine and escitalopram. L-DOPA/benserazide does not affect the striatal [18F]FE-PE2I binding in PD rats.
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Theses (Master's Degree_의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.